AAFP Builds Tool for Docs to Speak Out Against MU Stage 3

Oct. 26, 2015
The American Academy of Family Physicians (AAFP) has built a tool with the aim to help family doctors speak out against the recently-issued meaningful use Stage 3 final rule.

The American Academy of Family Physicians (AAFP) has built a tool with the aim to help family doctors speak out against the recently-issued meaningful use Stage 3 final rule.

On Oct. 6, the Centers for Medicare & Medicaid Services (CMS) released both the Stage 3 final rule and the Stage 2 modifications final rule together in a 752-page document. Specifically regarding the Stage 3 final rule, CMS announced a 60-day public comment period to facilitate additional stakeholder feedback.

Now, AAFP is taking a page out of the American Medical Association’s book, developing a Speak Out tool to help family physicians demand that their representatives do just that. More than 1,900 Academy members have called for a pause in MU Stage 3 through the Speak Out already. What’s more, AAFP says, their messages can be expected to find an attentive audience in Washington, where senators and more than 100 House members had asked for a delay just before the final Stage 3 rule was issued.

According to AAFP, “The message to legislators spells out the fact that MU stage three requirements make it more difficult for physicians to maintain the high standards their patients expect. If allowed to stand, the requirements will impose ‘significant financial strains’ on practices without doing much to improve the quality of patient care.”

Already, the number of physicians who have attested to MU has fallen dramatically, the message tells legislators. Fewer than 10 percent of physicians have attested to Stage 2, and 43 percent will face a penalty in 2015, according to AAFP. “To keep from driving even more physicians from the program, Congress must pass legislation to delay MU stage three until it is refocused to help physicians improve their care for patients,” the message says.

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1